Navigation Links
Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Date:10/18/2011

RICHMOND, Calif., Oct. 18, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2011 financial results on Tuesday, October 25, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 20389876.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 25, 2011 to midnight ET on November 1, 2011. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406 respectively. The conference ID number for the replay is 20389876.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of ZFP Therapeutics®, novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
2. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
3. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
4. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
5. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
7. Sangamo Announces Pricing of Public Offering of Common Stock
8. Sangamo Announces Public Offering of Common Stock
9. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
10. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
(Date:2/10/2016)... 10, 2016  Allergan plc (NYSE: AGN ) ... Brent Saunders , Allergan,s CEO and President, will be ... session at the RBC Capital Markets Healthcare Conference on ... The New York Palace Hotel in New ... live and can be accessed on Allergan,s Investor Relations ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... three states, announced today the promotion of two long-standing principal investigators (PI) to ... Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research ...
Breaking Biology Technology:
(Date:1/21/2016)... 2016 --> ... research report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, ... Expression, Voice Recognition and Others), Services, Application Areas, ... 2020", published by MarketsandMarkets, the global Emotion Detection ... 22.65 Billion by 2020, at a CAGR of ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):